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Muscle degeneration is a prevalent disease, particularly in aging societies where it has a huge impact on quality
of life and incurs colossal health costs. Suitable donor sources of smooth muscle cells are limited and minimally
invasive therapeutic approaches are sought that will augment muscle volume by delivering cells to damaged or
degenerated areas of muscle. For the first time, we report the use of highly porous microcarriers produced using
thermally induced phase separation (TIPS) to expand and differentiate adipose-derived mesenchymal stem cells
(AdMSCs) into smooth muscle-like cells in a format that requires minimal manipulation before clinical de-
livery. AdMSCs readily attached to the surface of TIPS microcarriers and proliferated while maintained in
suspension culture for 12 days. Switching the incubation medium to a differentiation medium containing 2 ng/
mL transforming growth factor beta-1 resulted in a significant increase in both the mRNA and protein ex-
pression of cell contractile apparatus components caldesmon, calponin, and myosin heavy chains, indicative of
a smooth muscle cell-like phenotype. Growth of smooth muscle cells on the surface of the microcarriers caused
no change to the integrity of the polymer microspheres making them suitable for a cell-delivery vehicle. Our
results indicate that TIPS microspheres provide an ideal substrate for the expansion and differentiation of
AdMSCs into smooth muscle-like cells as well as a microcarrier delivery vehicle for the attached cells ready for
therapeutic applications.
Introduction
Cell therapy as a form of regenerative medicine isbeing explored for an increasing number of clinical con-
ditions involving bone,1 cartilage,2 and cardiomyopathies.3
Urethral sphincter deficiency resulting in incontinence is a
condition that is also likely to benefit from this type of thera-
py.4–8 Smooth muscle provides an important function for a
number of physiological processes. This includes, for exam-
ple, peristaltic movements within the gastrointestinal tract,9
regulation of blood pressure,10 and maintaining ventilation of
the airways.11 The smooth muscle component provides im-
portant tonic or phasic contraction to these physiological
processes.12 Therefore, damage, degeneration, or loss of
smoothmuscle through injury and disease results in significant
morbidity and mortality. Technologies that will support
smooth muscle cell-based therapy are currently limited and
none is currently at a stage ready for clinical translation.
Treatment of coronary and peripheral artery disease using
small-molecule therapy and gene approaches has largely
failed to date13 and the focus has now shifted toward cell-
based approaches, with delivery of cells to injured vascu-
lature being potentially useful for the restoration of structure
and function. This has been demonstrated by Allaire et al.,
who used endovascular delivery of vascular smooth muscle
cells to improve the stability of aortic injuries.14 However,
one of the major limitations of cell-based regenerative
medicine therapy targeting smooth muscle is the lack of
donor tissue suitable for harvesting cells. The use of stem
cells as a source of smooth muscle for therapeutic purposes
has generated interest. Cell types being investigated include
embryonic stem cells, adult endothelial progenitor cells,
mesenchymal stem cells (MSCs), and induced pluripotent
stem cells.15,16
MSCs isolated from bone marrow and adipose tissue can
differentiate into osteoblasts,17 chondrocytes,18 adipocytes,19
and cardiomyocytes20 using biomaterials as a scaffold. How-
ever, limitations with bone marrow-derivedMSC isolation are
donor-site morbidity, pain, and inpatient recovery after biopsy
collection.21 For a large proportion of the population, visceral
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fat is a readily available tissue that contains an abundance of
MSCs that can be differentiated into a variety of tissues.22
Chemical, physical, and biological cues can be used to
drive the stem cell fate. The suitability of three-dimensional
scaffolds for culture and differentiation of MSCs is deter-
mined by their physical properties.23 This includes surface
topography, microstructure, and mechanical properties,
which will influence cell adhesion, proliferation, and dif-
ferentiation.24 The use of spherical microcarriers combined
with suspension bioreactors is a widely used technique to
expand anchorage-dependent cells.24–26 The microcarriers
provide a large surface area for cell adhesion and growth in
a homogeneous and controlled environment.
Moreover, the use of microcarriers may provide a more
favorable environment for the expansion of cell numbers
in vitro and their subsequent in vivo delivery for therapeutic
purposes. Cell expansion on two-dimensional (2D) sub-
strates requires their chemical and/or physical detachment
from the culture vessel before delivery. This process dis-
rupts cell adhesion to extracellular matrix proteins and may
damage the cell membranes resulting in changes to the
structure and function of the cells.27–29 The detrimental ef-
fects caused by this process are likely to reduce the efficacy
of the delivered cell product and contribute to poor clinical
outcomes.
Limitations associated with smooth muscle cell therapy
and approaches to in vitro cell culture have highlighted the
need for improvements in this area before this type of
therapy can be successfully translated into a clinical appli-
cation for humans. We have previously developed a novel
type of biodegradable polymer microcarrier intended for
minimally invasive treatment of incontinence and sphincter-
sparing treatment of fistulas that can be used for large-scale
expansion of cells.29–32 The microcarriers, composed of a
biocompatible and degradable material, poly(D,L-lactide-
co-glycolide) (PLGA), are prepared using a thermally in-
duced phase separation (TIPS) technique, resulting in a
highly porous structure that facilitates controlled degrada-
tion compared with solid microcarriers. We have demon-
strated the manufacture of TIPS microcarriers to be a
scalable process that can be performed under GMP condi-
tions, providing a clinically ready product.
The objective of the current study was to investigate the
use of TIPS microspheres for the in vitro expansion of
MSCs and their differentiation into smooth muscle-like cells
that might ultimately be used for cell therapy.
Materials and Methods
Preparation of PLGA TIPS microcarriers
PLGA TIPS microcarriers were prepared as previously
described.29 Briefly, 75:25 PLGA (Purasorb PDLG7507;
Purac Biomaterials) was dissolved in dimethylcarbonate
(DMC, 1:25 [w/v]; Sigma-Aldrich) using magnetic stirring
overnight. Microcarriers were fabricated from the polymer
solution using a Nisco Encapsulator Unit Var D (Nisco
Engineering), fitted with a stainless steel sapphire-tipped
nozzle with a 150-mm orifice. A polymer solution was fed
into the encapsulator unit by a syringe pump (Pump 11;
Harvard Apparatus), connected through a silicone tube, at a
constant rate of 3mL min - 1. The vibration frequency of the
nozzle was kept at 1.80 kHz and the amplitude of frequency
at 100%. Liquid polymer droplets were ejected into a
polyethylene beaker containing 400mL of liquid nitrogen.
The frozen droplets were allowed to equilibrate in the liquid
nitrogen and transferred to a 50-mL Falcon tube (BD
Biosciences). Samples were lyophilized using an Edwards
MicroModulyo freeze dryer (ThermoFisher Scientific) for
24 h to allow the sublimation of residual DMC. For the
experiments conducted in the current study, PLGA TIPS
microcarriers were sieved to produce batches with a size
range of 150–425 mm.
Attachment and growth of adipose-derived MSC
on PLGA TIPS microcarriers
PLGA TIPS microcarriers were prepared as outlined
above and preincubated under vacuum in a culture medium
(Alpha Minimal Essential Medium [a-MEM; Gibco] sup-
plemented with 10% fetal bovine serum [FBS; Gibco-
Invitrogen], 100UmL-1 penicillin, 100mgmL-1 streptomycin,
and 0.25mg mL-1amphotericin B [Sigma-Aldrich]; termed the
proliferation medium), as previously described.29 Human
adipose-derived mesenchymal stem cells (AdMSCs, Stem-
Pro; Invitrogen) were seeded on the TIPS microcarriers at a
density of 2000 cells/cm2 of equivalent microsphere surface
area in spinner flasks (MicroCarrier Spinner Flask Compo-
site 100mL, 1965-00100 [BellCo Glass], precoated with
Sigmacote [Sigma-Aldrich] to prevent cell attachment to the
flasks) containing 50mL of proliferation medium. TIPS
microcarriers in the spinner flasks were stirred by a poly-
tetrafluoroethylene paddle driven by an external magnetic
device (Variomag Magnetic Stirrer Biosystem Direct) in a
37C and 5% CO2 humidified incubator. For loading cells
onto the TIPS microcarriers, the stirring regimen consisted
of a 2-min stirring at 45 rpm followed by resting for 30min
over a period of 18 h. After 18 h of loading, the cellularized
TIPS microcarriers were allowed to settle and the medium
was replaced with 100mL of fresh proliferation medium.
Subsequently, the stirring was set at a continuous rate of
45 rpm. The cellularized TIPS microcarriers were incubated
in the proliferation medium for 12 days, after which the
medium was changed to either the a-MEM supplemented
with 2 ngmL- 1 TGF-b1 (PeproTech), 10% FBS, 100UmL- 1
penicillin, 100mg mL - 1 streptomycin, and 0.25 mg mL - 1
amphotericin B (termed the smooth muscle cell differenti-
ation medium) or the a-MEM supplemented with 10% FBS,
100U mL - 1 penicillin, 100mg mL - 1 streptomycin, and
0.25 mg mL - 1 amphotericin B (termed the control medium)
and incubated for a further 7 or 14 days. Fifty percent of the
culture medium was removed and replaced with a fresh
medium every 3 days.
Quantification of adipose-derived MSC growth
on PLGA TIPS microcarriers
The expansion of AdMSCs cultured on TIPS micro-
carriers was quantified at 1, 4, 8, 12, and 18 days after cell
seeding. At each time point, an equal volume of micro-
carriers (100mL) was removed from the spinner flasks and
the number of cells on the microcarriers determined using
the CellTiter 96 Aqueous nonradioactive cell proliferation
assay (Promega). The reaction product was transferred to a
96-well plate and the optical density measured using a mi-
croplate reader at 490 nm. The absorbance measurement for
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each sample was converted to the number of viable cells
using a standard curve derived from AdMSCs cultured on a
96-well plate. This figure was then used to calculate the
number of cells per microcarrier in each sample. The
number of TIPS microcarriers in each sample was counted
directly using light microscopy.
Quantitative polymerase chain reaction for smooth
muscle cell markers
Aliquots of cell-seeded TIPS microcarriers were lysed
with buffer RLT (Qiagen) containing 1% (v/v) b-mercap-
toethanol (Sigma) at 12, 19 (7 days postdifferentiation), and
26 days (14 days postdifferentiation) of culture. Total RNA
was isolated from the lysed cells using the RNeasy Mini Kit
(Qiagen) according to the manufacturer’s instructions. The
total RNA was eluted with 30mL RNase-free water. The
RNA concentration was quantified at an absorbance of
260 nm using Tecan Infinite M200 (Tecan Group).
Two hundred nanograms of extracted RNA from each
sample was reverse transcribed into single-stranded cDNA
using the High Capacity cDNA Reverse Transcription kit
(Applied Biosystems) following the manufacturer’s in-
structions. The RNA samples were subjected to reverse
transcription reaction at 25C for 10min followed by 37C
for 120min using a PTC-100 Programmable thermal con-
troller (MJ Research, Inc.).
Real-time PCR 7300 System (Applied Biosystems) was
used to amplify cDNA for each sample using human Taq-
Man Gene Expression Assays (Hs99999905-m1, GAPDH;
Hs00154543_m1, CNN1; Hs00263989_m1, CALD1;
Hs00224610_m1, MYH11) (Applied Biosystems). A total
reaction volume of 25mL was used comprising 1.25 mL
primers, 5 mL of single-stranded cDNA, 12.5 mL of TaqMan
Mastermix (Applied Biosystems), and 6.25 mL of RNase-
free water conducted in a 96-well reaction plate. Thermo-
cycling conditions consisted of exposure to 50C for 2min
followed by 95C for 10min and the subsequent 40 cycles
denaturation step at 95C for 15 s followed by 60C for
1min. Measurement of quantitative polymerase chain re-
action (qPCR) products was performed using the 7300 SDS
software relative to samples collected on day 12 and nor-
malized to the housekeeping gene, GAPDH.
In-cell Western for smooth muscle cell markers
TIPS microcarriers with AdMSCs attached to the surface
were aliquoted into 96-well plates (25– 5 microcarriers per
well) and washed in phosphate-buffered saline (PBS) fol-
lowed by fixation in 4% formaldehyde in PBS for 30min.
Cells were permeabilized by washing five times in 0.1%
triton X-100 in PBS for 5min per wash. Nonspecific binding
was blocked using the Odyssey blocking buffer (Li-Cor
Biosciences) for 1 h at room temperature. The samples were
incubated with anti-caldesmon (1:1000), anti-calponin
(1:1000), and anti-smooth muscle myosin heavy chain
(1:1000) antibodies (Sigma-Aldrich) at 4C overnight.
Samples were then washed extensively in PBS containing
0.1% Tween 20 five times for 5min per wash. Samples were
then incubated with the IR Dye 800 CW secondary antibody
(1:800) with the CellTag 700 stain (1:500; Li-Cor Bios-
ciences) in the Odyssey blocking buffer for 1 h at room
temperature. Samples were extensively washed in PBS
containing Tween 20 for 5min per wash. After a final wash,
all liquid was removed and the plate was scanned on the
Odyssey Classic Infrared Imaging System (Li-Cor Bios-
ciences) using both 700 and 800 nm detection channels at a
169 nm resolution, medium quality with a focus offset of
4.0mm. Quantitative in-cell Western analysis was performed
using Image Studio Lite version 3.1 (Li-Cor Biosciences).
Immunocytochemistry for smooth muscle cell markers
Cellularized TIPS microcarriers were fixed in 4% form-
aldehyde in PBS for 30min. The cells were permeabilized in
0.02% Triton X-100 (Sigma-Aldrich) in PBS for 10min
followed by incubation in 1% bovine serum albumin
(Sigma-Aldrich) in PBS for 30min to block nonspecific
binding. The samples were incubated with anti-a-SMA
(1:1000), anti-calponin (1:1000), or anti-caldesmon (1:1000)
(Sigma-Aldrich) for 1 h, washed extensively in PBS, fol-
lowed by incubation in an anti-mouse secondary antibody
(1:200, Alexa-Fluor 488; Molecular Probes) for 1 h. Isotype
control antibodies (mouse IgG1 and IgG2a; Sigma-Aldrich)
were used as control. The samples were stained with a
vector shield mounting medium for fluorescence with DAPI
(Vector Laboratories) and mounted on glass microscope
slides. The samples were viewed using a Leica TCS SP8
confocal microscope system (Leica).
TIPS microcarrier degradation in the presence
of smooth muscle cells
TIPS microcarriers were prepared as outlined in the
Preparation of PLGA TIPS Microcarriers section and incu-
bated in a culture medium consisting of Eagle’s Minimal
Essential Medium (EMEM; Sigma-Aldrich) supplemented
with 10% FBS (Gibco-Invitrogen), 100U mL - 1 penicillin,
100 mg mL - 1 streptomycin, 0.25 mg mL - 1amphotericin B
(Sigma-Aldrich), and 1% nonessential amino acids (Sigma-
Aldrich). Primary cultures of smooth muscle cells (porcine
aortic [P354–05]; European Collection of Cell Cultures)
were seeded on the microcarriers, using the regimen out-
lined in the Attachment and growth of adipose-derived MSC
on PLGA TIPS microcarriers section, at a density of 2000
cells/cm2 of microsphere surface area in 50mL of medium
in spinner flasks coated with Sigmacote (Sigma-Aldrich).
Subsequently, the stirring was set at a continuous rate of
45 rpm. PAOSMC-seeded PLGA TIPS microcarriers were
incubated in the above medium for 35 days. The control
group consisted of PLGA microcarriers without cells. Dur-
ing the culture period, 50% of the culture medium was re-
freshed every 3 days.
Following 35 days culture, PLGA microcarriers – cells
were washed in PBS. To detach cells, the microcarriers were
incubated in 0.1% sodium dodecyl sulfate (SDS; Invitrogen)
in deionized water for 120min in a sonicator water bath.
The samples were transferred into deionized water and
sonicated for 15min followed by 10-min sonication in 1%
(v/v) Triton X-100 (Sigma-Aldrich) in deionized water. The
samples were washed in deionized water and dried in a
vacuum oven. The absence of residual DNA in the micro-
carriers was determined using the DNeasy Blood & Tissue
Kit (Quiagen) to ensure complete removal of cellular debris.
Microcarrier degradation was evaluated by calculating the
percentage change in mass loss.
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The diameter of dry PLGA microcarriers at day 0 and 35
(decellularized and control samples) was measured from
digital images taken with a photomicroscope (Olympus BX
50) connected to a video camera (CoolSNAP-Pro Colour;
Media Cybernetics, Inc.). Image processing software
(Image-Pro Plus v. 4.5.0.19; Media Cybernetics, Inc.) was
used to determine the mean diameter of the microcarriers
(n = 25 per group).
Ultrastructural analysis of TIPS microcarriers. Scanning
electron microscopy (SEM) was used to assess the surface
topography of PLGA microcarriers. Cellularized micro-
carriers were fixed in 2.5% glutaraldehyde (Sigma-Aldrich)
in PBS for 15min, followed by dehydration through in-
creasing concentrations of ethanol (70%, 80%, 90%, 100%;
Sigma-Aldrich). The samples were transferred to hexa-
methyldisilazane (Sigma-Aldrich), mounted on aluminum
stubs using adhesive carbon tabs, and sputter coated with
gold/palladium (Polaron E5000). Samples were viewed
under a JEOL JSM-5410 LV SEM (JEOL) at 20 keV.
Statistical analysis. All experiments were repeated in
replicates of five, unless otherwise stated. The data were
analyzed using the unpaired two-tail Student’s t-test and
one-way analysis of variance with Dunnett’s multiple
comparison test using GraphPad Prism v.4.00 statistical
software (GraphPad Software). The data are presented as
mean – standard deviation. A p-value of < 0.05 indicated
statistical significance.
Results
AdMSC growth on TIPS microcarriers
AdMSCs were seeded on TIPS microcarriers and cultured
for a total of 18 days. The absorbance measurements derived
from the CellTiter assay performed on aliquots of micro-
carriers at different time intervals increased significantly
between days 1 and 4 ( p< 0.05), corresponding with a 35%
increase in the number of viable cells per microcarrier, and
between days 8 and 12 ( p < 0.01) corresponding with a 58%
increase in the number of viable cells per microcarrier (Fig.
1). The assay absorbance measurements reached a peak on
day 12 followed by a plateauing on day 18.
Expression of smooth muscle cell markers
TIPS microcarriers seeded with AdMSCs were cultured in
a proliferation medium for 12 days, after which the medium
was removed and replaced with either a smooth muscle cell
differentiation medium or control medium for a further 7 and
14 days before PCR was performed using relative quantifi-
cation. All data were normalized to the housekeeping gene
and compared to the threshold cycle (CT) value of the cali-
brator obtained at the beginning of the differentiation process
(day 12 postseeding). The expression of caldesmon, calponin,
and myosin heavy chain was increased significantly after 7
and 14 days of culture in the differentiation medium (Fig. 2
and Table 1). Cells cultured on TIPS microcarriers incubated
in the control medium did not express increased levels of
these markers at either time point.
In-cell Western protein analysis was performed using im-
munofluorescence quantification of the target protein in a cell
population. Protein detection was normalized to the cell
number for well-to-well population variation. Calponin ex-
pression was increased at days 7 and 14 after incubation in the
differentiation medium compared with the expression level at
day 1 ( p< 0.05), but not after incubation in the proliferation
medium at day 7 and 14 (Fig. 3). Caldesmon expression was
increased at days 7 and 14 in both the proliferation ( p< 0.01)
and differentiation medium ( p< 0.001) compared with the
expression level at day 1, with higher levels of expression in
cells incubated in the differentiation medium. The expression
of myosin heavy chain was significantly increased only at day
14 after incubation in the differentiation medium compared
with the expression level at day 1 ( p< 0.01).
FIG. 1. Cell attachment to the TIPS microcarriers. (a) The number of viable AdMSCs attached to the surface of PLGA
TIPS microcarriers increased up to day 12, after which the number plateaued indicating that confluence has been attained.
(b) Scanning electron microscopy (SEM) of the microcarriers at day 12 confirms the confluence of AdMSCs on the
microcarrier surface. AdMSCs, adipose-derived mesenchymal stem cells; PLGA, poly(D,L-lactide-co-glycolide); TIPS,
thermally induced phase separation (*p < 0.05, **p < 0.01).
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After 12 days of culture in the proliferation medium for
cellularization, AdMSCs expressed a-smooth muscle actin,
but calponin and caldesmon were not visible by immuno-
cytochemistry. Incubation in the differentiation medium for
a further 7 and 14 days resulted in the induced expression of
calponin and caldesmon (Fig. 4).
Degradation of TIPS microcarriers in the presence
of smooth muscle cells
TIPS microspheres prepared for use as microcarriers in
the current study exhibited characteristic structural features.
This included a highly porous surface, with the noncircular
pores measuring 1–5 mm, often appearing to be arranged in a
chevron-like pattern (Fig. 5a). The effect of smooth muscle
cell growth and metabolic activity on the degradation and
structural features of TIPS microcarriers in spinner flask
culture systems was assessed over a period of 35 days and
compared with noncellularized microcarriers. The diameter
of PLGA microcarriers under both conditions was signifi-
cantly reduced after 35 days compared with the starting
diameter of nondegraded microcarriers ( p< 0.001; Fig. 6).
The growth of cells on the surface of the microcarriers re-
sulted in no significant difference in the diameter of TIPS
microcarriers after 35 days compared with noncellularized
microcarriers degraded for the same amount of time.
The dry mass of TIPS microcarriers – cells was also sig-
nificantly reduced ( p < 0.0001) after 35 days incubation in
the spinner flask system. There was no significant difference
in mass loss between TIPS microcarriers seeded with cells
and those without cells.
Surface ultrastructural features of the microcarriers were
changed after incubation for 35 days in the spinner flasks.
Most notably, the surface of the microcarriers no longer
contained pores arranged in a chevron-like pattern. Instead,
the pores had become more circular and less abundant, with
the surface also appearing to be smoother (Fig. 5b). This
change in structural features did not appear to be influenced
by the presence of cells cultured on the surface of the mi-
crocarriers, as revealed after decellularization (Fig. 5c).
Discussion
Sourcing sufficient quantities of smooth muscle cells and
their delivery in an optimal format for therapeutic purposes
poses a challenge that is hindering the development of new
therapies for a wide range of diseases. The current study
demonstrates the feasibility of attaching, expanding, and
differentiating AdMSCs into smooth muscle-like cells on
the surface of clinically ready TIPS microcarriers. It is en-
visaged that delivery of cellularized TIPS microcarriers di-
rectly to targetmusclewill avoid detrimental effects associated
with cell detachment procedures used with conventional cell
FIG. 2. Expression levels of caldesmon, calponin, and
myosin heavy chain mRNA at 7 and 14 days culture in a
differentiation or control medium relative to expression after
12 days of incubation in a proliferation medium (*p < 0.05,
**p < 0.01, ***p < 0.001).
Table 1. Change in mRNA Expression After 7
and 14 Days Incubation in Differentiation
Medium Relative to Cells Incubated
in Proliferation Medium for 12 Days
Change in
expression at day 7
Change in
expression at day 14
Control Differentiation Control Differentiation
Caldesmon ns p < 0.001 ns p < 0.001
Calponin ns p < 0.01 ns p< 0.0001
Myosin
heavy
chain
ns p < 0.01 ns p< 0.05
ns, not significant.
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culture techniques. Furthermore, this approach has the addi-
tional benefit of being minimally invasive with targeted de-
livery to the site requiring regeneration. Once delivered into
damaged or dysfunctional smooth muscle, we have shown that
the cells are likely to migrate from the microcarriers and inte-
grate with host tissue.29
Our previous studies have demonstrated that in vitro
smooth muscle cells rapidly attach to the surface of the
PLGA TIPS microcarriers and increase in number when
cultured in suspension bioreactors.29 This approach offers
advantages for the expansion of smooth muscle cells in vitro
before in vivo delivery of cellularized microcarriers. How-
ever, suitable donor sites for harvesting smooth muscle cells
are not readily available. To address this need, other groups
have investigated the ability to transdifferentiate skeletal
muscle-derived stem cells into smooth muscle cells us-
ing growth factor-immobilized poly caprolactone/Pluronic
F127 porous microbeads.33 While the inclusion of bioactive
components into the microcarrier system was shown to have
a positive effect on smooth muscle cell differentiation, it
would require careful consideration from a regulatory per-
spective if it were to be implanted in vivo. The current study
aimed to explore the ability of TIPS microcarriers to facil-
itate the expansion of AdMSCs and their differentiation into
smooth muscle-like cells, as well as evaluating the effect of
smooth muscle cellularization on microcarrier degradation,
which could have an impact on the clinical use of the pro-
posed therapeutic system.
Cell expansion on the microcarriers increased up to day
12 incubation, after which the number of cells plateaued,
which coincided with cell confluence on the surface of the
microcarriers. TIPS microcarriers with confluent layers of
cells were transferred into the differentiation medium at day
12 and incubated for a further 7 or 14 days to evaluate
induction of AdMSC differentiation into smooth muscle-
like cells. Differentiation was achieved primarily by the
inclusion of 2 ng/mL TGF-b1 in the differentiation culture
medium. A similar approach has previously been used to
induce differentiation of MSCs into smooth muscle-like
cells when cultured on 2D tissue culture surfaces.34,35 Dif-
ferentiation following TGF-b1 binding results in signal-
ing through the Smad pathway, causing inhibition of cell
FIG. 3. In-cell Western data showing the expression lev-
els of caldesmon, calponin, and myosin heavy chain protein
at 7 and 14 days culture in a differentiation or control
proliferation medium compared with the expression at day 1
in a proliferation medium (n = 4) (*p< 0.05, **p < 0.01,
***p < 0.001).
FIG. 4. Immunocytochemistry showing expression of
calponin in cells attached to PLGA TIPS microcarriers
cultured in a differentiation medium for 14 days. Color
images available online at www.liebertpub.com/tec
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proliferation and induction of contractile proteins in smooth
muscle cells.34–36
Incubation of the TIPS microcarriers in the differentiation
medium resulted in the induced expression of the three
myogenic markers—caldesmon, calponin, and myosin hea-
vy chains. These markers are intermediate to late markers of
smooth muscle cell differentiation, unlike a-smooth muscle
actin, which is considered to be an early marker of smooth
muscle differentiation and, importantly, is not limited only
to expression in smooth muscle cells.35 The mRNA and
protein expression for these contractile apparatus markers
was significantly higher for cells attached to the micro-
carriers and incubated in TGFb-1 compared with the mi-
crocarriers incubated in the control medium when quantified
by QPCR and in-cell Western, indicating that TGFb-1 en-
hanced the differentiation process. The expression of
myosin heavy chain was only significantly expressed in
cells incubated in the differentiation medium for 14 days
( p < 0.01). In our study, cells attached to the TIPS micro-
spheres may be in an intermediate stage of smooth muscle
differentiation, with upregulation of caldesmon and calponin
at 7 days, and myosin heavy chain, a late smooth muscle
contractile marker at day 14. Our findings are supported by a
study by Narita et al., where MSC differentiation into
smooth muscle-like cells using a defined differentiation
medium containing TGFb-1 caused mRNA upregulation of
calponin and caldesmon, but not smooth muscle myosin
heavy chain.37 Surprisingly, immunocytochemistry revealed
the expression of caldesmon and calponin in cells incubated
in the control medium at day 7 and 14 postincubation in the
proliferation medium. While this result was unexpected,
spontaneous differentiation in the absence of TGFb-1 might
have occurred due to the confluent density of the cells on the
surface of the microcarriers, or through the effect of auto-
crine/paracrine factors released by the cells, or the shear
effect of incubating cells in the spinner flasks, as described
elsewhere.38,39 Myosin heavy chain was not detected by
immunocytochemistry at day 14.
The PLGA TIPS microcarriers used in the current study
initially had a highly porous surface structure, typical of
microspheres produced using the TIPS manufacturing pro-
cess.29,31,40 Relative to solid microcarriers, TIPS micro-
carriers of an equal size contain approximately 80–90% less
polymer material.40 This is advantageous as less degradation
FIG. 5. SEM images showing the surface of TIPS microcarriers (insets show the surface at higher magnification). (a)
Nondegraded TIPS microcarrier preincubation. (b) TIPS microcarrier after incubation for 35 days in the absence of cells. (c)
TIPS microcarrier after incubation for 35 days in the presence of cells. The cells were removed before imaging (scale bars:
main figures, 50 mm; inset, 5 mm).
FIG. 6. Degradation of TIPS microcarriers in the presence
of smooth muscle cells. (a) Percentage change in the mass
of PLGA TIPS microcarriers relative to the starting mass
after 35 days incubation – cellularization with smooth
muscle cells. (b) Reduction in the mean diameter of PLGA
TIPS microcarriers relative to the starting diameter after 35
days incubation – cellularization with smooth muscle cells
(***p < 0.001).
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products are produced as the microcarriers degrade to be
replaced by host tissue.
The open porous structure also allows surface erosion to
occur rather than an autocatalytic process that is associated
with solid PLGA microspheres due to entrapment and ac-
cumulation of acidic degradation products. In vitro degra-
dation of TIPS microcarriers in the current indicates a
change in the pore structure over time; however, pores were
still visible at day 35. Porosity of the TIPS microspheres
will influence the shortest linear distance through the open
porous structure is a key factor, which will affect oxygen
and nutrient diffusion rates to cells infiltrated within the
interconnected pores and central cavity.41
Degradation of the microcarriers in the current study was
also assessed using fully differentiated smooth muscle cells
cultured on the surface of microcarriers for up to 35 days.
This approach was used to provide an indication of the
likely effects of microcarrier degradation following their
implantation into smooth muscle tissues. While the fully
differentiated smooth muscle cells were derived from por-
cine aorta, they provided a useful surrogate cell type for
testing the degradation activity of smooth muscle cells
on the microcarrier. Both cellularized and control non-
cellularized microcarriers exhibited a significant decrease in
their diameters after 35 days of dynamic culture in the
spinner flasks. The presence of cells on the microcarrier
surface did not produce any observable change to the deg-
radation process of the PLGA microcarriers, indicating that
degradation of the microcarriers is likely to occur in a
predictable manner. To substantiate these findings and to
fulfill the requirements of regulatory authorities, preclinical
safety studies will be required, which will initially investi-
gate the implantation and degradation of noncellularized
microcarriers into target smooth muscle tissues.
We have previously shown that the porosity of TIPS
microspheres prepared from the same polymer composition
to that used in the current study will allow cell infiltration
inside the microspheres.29 We have also shown that TIPS
microspheres retain an open scaffold structure when im-
planted in vivo, which facilitates rapid tissue infiltration and
integration at the site of implantation, thus reducing the
possibility of migration from the target site.40
Results from the current study indicate that it is possible
to achieve smooth muscle-like cells from AdMSCs when
incubated on TIPS microcarriers. Further studies will be
necessary to prove that the differentiated cells are capable of
providing phasic and tonic contractile properties similar to
native smooth muscle and that they can restore damaged or
lost smooth muscle function.
We have shown that it is feasible to use TIPS micro-
carriers to produce a stem cell-derived smooth muscle cell
construct, which avoids the need to harvest donor smooth
muscle cells, provides a minimally invasive approach for
smooth muscle cell-based delivery, and addresses an unmet
need for regenerative medicine.
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